Brief: Fennec Pharmaceuticals Says Pedmark Receives Orphan Drug Exclusivity From U.S. FDA
31/01/2023 13:41
Jan 31 (Reuters) - Fennec Pharmaceuticals Inc FENC.O :
* FENNEC PHARMACEUTICALS ANNOUNCES PEDMARK® (SODIUM
THIOSULFATE
INJECTION) RECEIVES ORPHAN DRUG EXCLUSIVITY FROM U.S. FDA
* FENNEC PHARMACEUTICALS - ORPHAN DRUG EXCLUSIVITY PROVIDES
7 YRS
OF MARKET EXCLUSIVITY FOR PEDMARK FROM FDA APPROVAL ON SEPT 20,
2022 UNTIL SEPT 20, 2029
Source text for Eikon: ID:nGNX2xhkQ9
Further company coverage: FENC.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Fennec Pharmaceuticals
See all newsFennec Pharmaceuticals Inc. reports results for the quarter ended June 30 - Earnings Summary
Fennec Pharmaceuticals Q2 sales rise on PEDMARK demand
Fennec Pharmaceuticals Inc. expected to post earnings of 1 cent a share - Earnings Preview
Fennec Pharmaceuticals Q1 sales rise 73% on PEDMARK demand
U.S. STOCKS ON THE MOVE-UnitedHealth, Intel, Apple